health biotech news today obesity drugs glp-1 Unpacking $100B+ Market Opportunity: What It Means for Biopharma, Payers, and Providers Novartis, Alector, Merck, Alnylm, UniQure
Description
M.YueZ.MorgenweckJ.et al (2017)
Healthcare professionals can provide guidance on when to safely resume therapy
And worth being rigorous about
Just recently there was a, a big analysis, and I think that found that GLP-1 drugs were linked to a higher risk of skeletal disorders, so things like osteoporosis
Journal of Biological Chemistry 29435143531
T2DM patients have much higher SGLT2 expression in their kidneys than do healthy individuals
